润迈德-B(02297)：caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》_老虎社区_美港股上老虎

润迈德-B(02297)：caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》

智通财经2022-12-28

智通财经APP讯，润迈德-B(02297)公布，集团的核心产品caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》。根据该专家共识，caFFR系统无需导丝与血管扩张药物即可进行冠状动脉功能学评价，操作简单，易于学习，节省测量时间，拓宽了适用人群，降低了技术风险。大量的临床证据已经证明caFFR系统的诊断准确性、临床适应症及预后价值，更多的临床证据将会不断涌现。随着临床证据...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

不知未来
·2023-01-24
为什么上市以来一直下跌，市值一直萎缩，股价下跌80%是否公司出什么大事没发公告出来，还是人为问题？如：操纵杀跌？
回复
9
举报
收起
- 共享快乐:
  过来看看
  2023-01-24
  回复
  举报
- Allen moft:
  e
  2023-01-24
  回复
  举报
- Hdjdjhsj:
  po ho
  2023-01-24
  回复
  举报
查看更多 2 条评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2294985825?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-12-28 17:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2294985825","market":"sh","top_or_hot":-1,"title":"润迈德-B(02297)：caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》","media":"智通财经","content":"<div>\n<p>智通财经APP讯，润迈德-B(02297)公布，集团的核心产品caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》。根据该专家共识，caFFR系统无需导丝与血管扩张药物即可进行冠状动脉功能学评价，操作简单，易于学习，节省测量时间，拓宽了适用人群，降低了技术风险。大量的临床证据已经证明caFFR系统的诊断准确性、临床适应症及预后价值，更多的临床证据将会不断涌现。随着临床证据...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/853624.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>润迈德-B(02297)：caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n润迈德-B(02297)：caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-28 17:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/853624.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，润迈德-B(02297)公布，集团的核心产品caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》。根据该专家共识，caFFR系统无需导丝与血管扩张药物即可进行冠状动脉功能学评价，操作简单，易于学习，节省测量时间，拓宽了适用人群，降低了技术风险。大量的临床证据已经证明caFFR系统的诊断准确性、临床适应症及预后价值，更多的临床证据将会不断涌现。随着临床证据...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/853624.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02297","symbol_name":"润迈德-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/853624.html","article_id":"2294985825","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2294985825","pubTimestamp":1672220164,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，润迈德-B 公布，集团的核心产品caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》。同时，caIMR系统作为全球领先的无介入微循环病变诊疗系统，突破性地实现了微血管功能的无创定量评估。caFFR系统和caIMR系统的联合诊断可定量评估心外膜下冠脉狭窄或微小动脉病变导致的心肌缺血，进行相应的治疗决策，这将推动冠脉介入精准医疗的发展。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02297":"润迈德-B","BK1100":"医疗保健设备"},"translate_title":"Runmaide-B (02297): caFFR system and caIMR system were included in the Expert Consensus of Computational Coronary Physiology Detection Technology in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02297":1},"content_text":"智通财经APP讯，润迈德-B(02297)公布，集团的核心产品caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》。根据该专家共识，caFFR系统无需导丝与血管扩张药物即可进行冠状动脉功能学评价，操作简单，易于学习，节省测量时间，拓宽了适用人群，降低了技术风险。大量的临床证据已经证明caFFR系统的诊断准确性、临床适应症及预后价值，更多的临床证据将会不断涌现。随着临床证据的积累，caFFR系统有望替代导丝测量FFR成为指导血运重建的常规手段，推动心肌缺血的功能学评估在国内外的普及与应用。同时，caIMR系统作为全球领先的无介入微循环病变诊疗系统，突破性地实现了微血管功能的无创定量评估。 caFFR系统和caIMR系统的联合诊断可定量评估心外膜下冠脉狭窄或微小动脉病变导致的心肌缺血，进行相应的治疗决策，这将推动冠脉介入精准医疗的发展。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":626565086,"gmtCreate":1674527174845,"gmtModify":1674528854669,"author":{"id":"4110571816671610","authorId":"4110571816671610","name":"不知未来","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4110571816671610","authorIdStr":"4110571816671610"},"htmlText":"为什么上市以来一直下跌，市值一直萎缩，股价下跌80%是否公司出什么大事没发公告出来，还是人为问题？如：操纵杀跌？","listText":"为什么上市以来一直下跌，市值一直萎缩，股价下跌80%是否公司出什么大事没发公告出来，还是人为问题？如：操纵杀跌？","text":"为什么上市以来一直下跌，市值一直萎缩，股价下跌80%是否公司出什么大事没发公告出来，还是人为问题？如：操纵杀跌？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":10,"repostSize":0,"link":"https://laohu8.com/post/626565086","repostId":2294985825,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7844545,"gmtCreate":1674530175605,"gmtModify":1674533304141,"authorId":4118901347312970,"author":{"id":4118901347312970,"idStr":"4118901347312970","authorId":4118901347312970,"name":"共享快乐","avatar":"https://static.tigerbbs.com/031a1d764d243beb971e11bdb712536a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":626565086,"type":1,"supId":0,"prevId":0,"content":"过来看看","text":"过来看看","html":"过来看看"},{"id":7844568,"gmtCreate":1674530942588,"gmtModify":1674530955747,"authorId":4114797862927240,"author":{"id":4114797862927240,"idStr":"4114797862927240","authorId":4114797862927240,"name":"Allen moft","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":626565086,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">e</span>","text":"<span class=\"s1\">e</span>","html":"<span class=\"s1\">e</span>"},{"id":7844567,"gmtCreate":1674530938275,"gmtModify":1674530951624,"authorId":4103012405740810,"author":{"id":4103012405740810,"idStr":"4103012405740810","authorId":4103012405740810,"name":"Hdjdjhsj","avatar":"https://static.tigerbbs.com/59d6bc0eecd5e2ab29d590759c3fdfd3","vip":1,"currentWearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":626565086,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">po ho</span>","text":"<span class=\"s1\">po ho</span>","html":"<span class=\"s1\">po ho</span>"},{"id":7844563,"gmtCreate":1674530820300,"gmtModify":1674530833564,"authorId":4103012405740810,"author":{"id":4103012405740810,"idStr":"4103012405740810","authorId":4103012405740810,"name":"Hdjdjhsj","avatar":"https://static.tigerbbs.com/59d6bc0eecd5e2ab29d590759c3fdfd3","vip":1,"currentWearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":626565086,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">h h h h h</span>","text":"<span class=\"s1\">h h h h h</span>","html":"<span class=\"s1\">h h h h h</span>"},{"id":7844562,"gmtCreate":1674530812330,"gmtModify":1674530825660,"authorId":4103012405740810,"author":{"id":4103012405740810,"idStr":"4103012405740810","authorId":4103012405740810,"name":"Hdjdjhsj","avatar":"https://static.tigerbbs.com/59d6bc0eecd5e2ab29d590759c3fdfd3","vip":1,"currentWearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":626565086,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">h h h h</span>","text":"<span class=\"s1\">h h h h</span>","html":"<span class=\"s1\">h h h h</span>"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}